MYD88 and neoplasm: Wang and colleagues (2010) report upon 5 year follow-up of 108 mixed stage CRC participants, 53 participants had tumor recurrence (DFS rate: 49%), with participants exhibiting high expression of TLR4 and its accessory protein MyD88 displaying increased recurrence rates compared to those with low expression (TLR4 + MyD88 (low vs high) 5-year DFS HR (95% CI) = 2.25 (1.27–3.99) P = 0.0053) (Wang et al. 2010).